Medthority· @Medthority · X·· 11 小时前评分70
正文 · 原文
#ESMO26
ASTRIDE provided US data supporting serplulimab in ES-SCLC, with outcomes consistent with the phase 3 ASTRUM-005 trial.
📊 2-year OS: 32.2% vs 17.6% 📊 Median PFS: 5.4 vs 4.9 months
No new safety signals identified.
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX
18 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
来源：Medthority · x.com